Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 194

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 194
---
5–10%. While less effective than newer options, it remains a widely prescribed option, especially for those who may not tolerate more potent agents.

Other Approved Medications

| ● | Orlistat                                                                                  
 (Alli, Xenical): A lipase inhibitor that prevents fat absorption in the intestine. It’s   
 over the counter in many markets but often associated with gastrointestinal side effects. |

| ● | Phentermine/Topiramate                                                   
 (Qsymia): A combination drug that reduces appetite and enhances satiety. |

| ● | Naltrexone/Bupropion                                                                     
 (Contrave): A combination affecting central nervous system pathways involved in appetite 
 regulation.                                                                              |

Cost Overview

| ● | Wegovy:                                      
 Approx. $1,300 to $1,500/month (U.S. market) |

| ● | Zepbound:            
 Approx. $1,060/month |

| ● | Saxenda:             
 Approx. $1,300/month |

| ● | Orlistat:                      
 ~$50–$100/month (OTC versions) |

| ● | Qsymia                                                                            
 and Contrave: Range between $150–$300/month, depending on insurance and discounts |

| Moore Financial Consulting |

| SKNY Pharmaceuticals, Inc. | April 2025    |
| Valuation                  | Page 13 of 25 |

Prices vary widely by region and are significantly impacted by insurance coverage, generics availability, and regulatory policies.

Surgical Interventions

For individuals with severe obesity (typically BMI ≥40, or ≥35 with comorbidities), bariatric surgery remains the most effective long-term treatment. Procedures such as gastric bypass, sleeve gastrectomy, and adjustable gastric banding alter the digestive system to limit food intake and/or nutrient absorption.

Bariatric surgery can lead to 30–40% weight loss and often results in the remission of obesity-related conditions like type 2 diabetes. However, it carries risks of surgical complications and long-term nutritional deficiencies, and access remains limited due to cost and capacity.

Weight Loss Epidemiology

As mentioned above, the combined overweight and obesity rates in North America are amongst the world’s highest. Mexico and the US have the highest overweight and obesity rates (75% and 73.6% respectively), followed by Canada (65.7%).

In the U.S., approximately 6% of adultsreport currently using GLP-1 receptor agonists, such as Ozempic or Mounjaro 1